Compare · MGRX vs PGNY
MGRX vs PGNY
Side-by-side comparison of Mangoceuticals Inc. (MGRX) and Progyny Inc. (PGNY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MGRX and PGNY operate in Misc Health and Biotechnology Services (Health Care), so they compete in similar markets.
- PGNY is the larger of the two at $1.42B, about 201.1x MGRX ($7.1M).
- Over the past year, MGRX is down 75.8% and PGNY is down 20.1% - PGNY leads by 55.8 points.
- PGNY has hit the wire 5 times in the past 4 weeks while MGRX has been quiet.
- PGNY has more recent analyst coverage (25 ratings vs 0 for MGRX).
- Company
- Mangoceuticals Inc.
- Progyny Inc.
- Price
- $0.43+8.01%
- $18.18+2.89%
- Market cap
- $7.1M
- $1.42B
- 1M return
- +34.71%
- +2.42%
- 1Y return
- -75.84%
- -20.05%
- Industry
- Misc Health and Biotechnology Services
- Misc Health and Biotechnology Services
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2023
- 2019
- News (4w)
- 0
- 5
- Recent ratings
- 0
- 25
Progyny Inc.
Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
Latest MGRX
- SEC Form 10-K filed by Mangoceuticals Inc.
- SEC Form NT 10-K filed by Mangoceuticals Inc.
- SEC Form 4 filed by Cohen Jacob D.
- SEC Form 4 filed by Cohen Jacob D.
- Mangoceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Mangoceuticals Announces Lawsuit Seeking Damages Exceeding $73 Million Against Former Technology Consulting and Software Development Firm, Clarity Ventures, Inc.
- Mangoceuticals, Inc. Announces PCT Patent Filing for MGX-0024 Antiviral Technology to Include Inhibiting Respiratory or Orally Acquired Virus Infection in Animals or Birds
- Mangoceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Mangoceuticals' Patented MGX-0024 Achieves Zero Respiratory-Related Mortality in 29,000-Bird Field Trials and Demonstrates Prophylactic Benefit Against H5N1 in Controlled Government Study
- Mangoceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
Latest PGNY
- Progyny, Inc. Announces Details for Its First Quarter 2026 Results Report
- SEC Form 4 filed by Cummings Melissa B
- Progyny Expands Access to Fertility and Women's Health with Industry's First Fully Insured Supplemental Plan
- SEC Form DEFA14A filed by Progyny Inc.
- SEC Form DEF 14A filed by Progyny Inc.
- Progyny Commemorates 10 Years of Redefining Women's Health and Family Building Care
- SEC Form PRE 14A filed by Progyny Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Progyny Inc.
- SEC Form 4 filed by Clapp Geoffrey
- Progyny Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits